Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) CEO Don M. Bailey sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $87.05, for a total value of $3,482,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) traded up 1.46% on Thursday, hitting $88.43. 1,859,260 shares of the company’s stock traded hands. Questcor Pharmaceuticals has a 1-year low of $33.00 and a 1-year high of $90.97. The stock has a 50-day moving average of $78.02 and a 200-day moving average of $65.65. The company has a market cap of $5.230 billion and a P/E ratio of 16.46. Questcor Pharmaceuticals also was the target of some unusual options trading on Wednesday. Traders acquired 11,206 put options on the company. This is an increase of approximately 104% compared to the average daily volume of 5,484 put options.

Questcor Pharmaceuticals (NASDAQ:QCOR) last issued its quarterly earnings data on Monday, April 28th. The company reported $1.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.61 by $0.21. The company had revenue of $227.10 million for the quarter, compared to the consensus estimate of $239.81 million. During the same quarter in the previous year, the company posted $0.76 earnings per share. The company’s revenue for the quarter was up 68.1% on a year-over-year basis. On average, analysts predict that Questcor Pharmaceuticals will post $6.89 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Tuesday, July 8th. Stockholders of record on Tuesday, July 1st will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 1.38%.

A number of analysts have recently weighed in on QCOR shares. Analysts at Piper Jaffray downgraded shares of Questcor Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Monday. They now have a $98.00 price target on the stock, up previously from $96.00. Separately, analysts at Oppenheimer reiterated an “outperform” rating on shares of Questcor Pharmaceuticals in a research note on Monday, April 21st. They now have a $86.00 price target on the stock, down previously from $99.00. Finally, analysts at Mizuho cut their price target on shares of Questcor Pharmaceuticals from $93.00 to $92.00 in a research note on Tuesday, April 8th. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $84.20.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.